Drug
Belantamab Mafodotin
Belantamab Mafodotin: highest development phase Phase 2, developed by GlaxoSmithKline. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| Belantamab Mafodotin NCT04676360 | Phase 2 | Relapsed Plasmablastic Lymphoma |
| Belantamab mafodotin NCT04126200 | Phase 1/2 | Multiple Myeloma |
| Belantamab mafodotin NCT04091126 | Phase 1 | Multiple Myeloma |
Latest
No recent events.
Follow Belantamab Mafodotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.